Mucosal graft-vs-host disease

Oral Diseases

Volumn 13, Issue 6, 2007, Pages 519-529

  Lew, J ^a   Smith, J A ^a  

^a NATIONAL EYE INSTITUTE   (United States)

Author keywords

Inflammatory disease; Mucosa; Stem cell transplantation

Indexed keywords

AZATHIOPRINE; BECLOMETASONE; BUDESONIDE; CLOFAZIMINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DACLIZUMAB; DEXAMETHASONE; ESTROGEN; HYDROXYCHLOROQUINE; LIDOCAINE; METHOTREXATE; METHOXSALEN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PALIFERMIN; PENTOSTATIN; RAPAMYCIN; RETINOIC ACID; RITUXIMAB; STEROID; TACROLIMUS; THALIDOMIDE;

CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL TRIAL; CONJUNCTIVITIS; EYE DISEASE; GASTROINTESTINAL DISEASE; GYNECOLOGIC DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MOUTH DISEASE; MOUTH HYGIENE; MUCOSAL DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; STOMATITIS; WHOLE BODY RADIATION;

CONJUNCTIVITIS; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LACRIMAL APPARATUS; MUCOUS MEMBRANE; SCLERITIS; STOMATITIS; VAGINITIS; XEROSTOMIA;

EID: 35348972933     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/j.1601-0825.2007.01412.x     Document Type: Review

References (101)

1. Ahmad SM, Stegman Z, Fruchtman S, Asbell PA (2002). Successful treatment of acute ocular graft-versus-host disease with tacrolimus (FK506). Cornea 21 : 432 433.
2. Akpek G, Chinratanalab W, Lee LA et al (2003). Gastrointestinal involvement in chronic graft-versus-host disease: a clinicopathologic study. Biol Blood Marrow Transplant 9 : 46 51.
3. Aoki S, Mizote H, Minamoto A, Suzuki M, Mishima HK, Tanaka H (2005). Systemic FK506 improved tear secretion in dry eye associated with chronic graft versus host disease. Br J Ophthalmol 89 : 243 244.
4. Aronni S, Cortes M, Sachetti M et al (2006). Upregulation of ICAM-1 expression in the conjunctiva of patients with chronic graft-versus-host disease. Eur J Ophthalmol 16 : 17 23.
5. Atkinson K, Weller P, Ryman W, Biggs J (1986). PUVA therapy for drug-resistant graft-versus-host disease. Bone Marrow Transplant 1 : 227 236.
6. Atkinson K, Horowitz MM, Gale R et al (1990). Risk factors for chronic graft-versus-host disease after HLA-identical sibling bone marrow transplantation. Blood 75 : 2459 2464.
7. Billingham RE (1966). The biology of graft-versus-host reactions. Harvey Lect 62 : 21 78.
8. Blaise D, Kuentz M, Fortaneier C et al (2000). Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Societe Francaise de Greffe de Moelle. J Clin Oncol 18 : 537 546.
9. Blazar BR, Weisdorf DJ, Defor T et al (2006). Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Blood 108 : 3216 3222.
10. Bruner RJ, Farag SS (2003). Monoclonal antibodies for the prevention and treatment of graft-versus-host disease. Semin Oncol 30 : 509 519.
11. Canninga-van Dijk MR, van der Straaten HM, Fijnheer R, Sanders CJ, van den Tweel JG, Verdonck LF (2004). Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease. Blood 104 : 2603 2606.
12. Carlens S, Ringden O, Remberger M et al (1998). Risk factors for chronic graft-versus-host disease after bone marrow transplantation: a retrospective single centre analysis. Bone Marrow Transplant 22 : 755 761.
13. Cheung MC, Nune GC, Hwang DG, Sutter EE, Duncan JL (2004). Acute zonal occult outer retinopathy in a patient with graft-versus-host disease. Am J Ophthalmol 138 : 1058 1060.
14. Clift RA, Buckner CD, Appelbaum FR, Sullivan KM, Storb R, Thomas ED (1998). Long-term follow-Up of a randomized trial of two irradiation regimens for patients receiving allogeneic marrow transplants during first remission of acute myeloid leukemia. Blood 92 : 1455 1456.
15. Clift RA, Radich J, Appelbaum FR et al (1999). Long-term follow-up of a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide for patients receiving allogenic marrow transplants during chronic phase of chronic myeloid leukemia. Blood 94 : 3960 3962.
16. Corson SL, Sullivan K, Batzer F, August C, Storb R, Thomas ED (1982). Gynecologic manifestations of chronic graft-versus-host disease. Obstet Gynecol 60 : 488 492.
17. Couriel D, Carpenter PA, Cutler C (2006). Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant 12 : 375 396.
18. Cutler C, Giri S, Jeyapalan S, Paniagua D, Viswanathan A, Antin JH (2001). Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol 19 : 3685 3691.
19. Cutler C, Miklos D, Kim HT et al (2006). Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 108 : 756 762.
20. Dausset JBH (1957). Identical nature of the leucocyte antigens detectable in monozygotic twins by means of immuno iso-leuco-agglutins. Nature 180 : 1430.
21. Deeg HJ, Antin JH (2006). The clinical spectrum of acute graft-versus-host disease. Semin Hematol 43 : 24 31.
22. Dudek AZ, Mahaseth H, DeFor TE, Weisdorf DJ (2003). Bronchiolitis obliterans in chronic graft-versus-host disease: analysis of risk factors and treatment outcomes. Biol Blood Marrow Transplant 9 : 657 666.
23. Elad S, Garfunkel AA, Enk CD, Galili D, Or R (1999). Ultraviolet B irradiation: a new therapeutic concept for the management of oral manifestations of graft-versus-host disease. Oral Surg Oral Med Oral Pathol Oral Radiol Endo 88 : 444 450.
24. Farmer ER (1986). The histopathology of graft-versus-host disease. Adv Dermatol 1 : 173 188.
25. Fawzi AA, Cunningham ET Jr. (2001). Central serous chorioretinopathy after bone marrow transplantation. Am J Ophthalmol 131 : 804 805.
26. Ferrara JL, Reddy P (2006). Pathophysiology of graft-versus-host disease. Semin Hematol 43 : 3 10.
27. Filipovich AH, Weisdorf D, Pavletic S et al (2005). National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 11 : 945 956.
28. Franklin RM, Kenyon KR, Tutschka PJ, Saral R, Green WR, Santos GW (1983). Ocular manifestations of graft-versus-host disease. Ophthalmology 90 : 4 13.
29. Giaccone L, Martin P, Carpenter P et al (2005). Safety and potential efficacy of low-dose methotrexate for treatment of chronic graft-versus-host disease. Bone Marrow Transplant 36 : 337 341.
30. Gleichmann E, Pals S, Rolink AG, Radaszkiewicz T, Gleichmann H (1984). Graft-versus-host reactions: clues to the etiopathology of a spectrum of immunologic diseases. Immunol Today 5 : 324 332.
31. Greinix HT, Volc-Platzer B, Rabitsch W et al (1998). Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. Blood 92 : 3098 3104.
32. Hassan AS, Clouthier SG, Ferrara JL et al (2005). Lacrimal gland involvement in graft-versus-host disease: a murine model. Invest Ophthalmol Vis Sci 46 : 2692 2697.
33. Heldal D, Tjonnfjord G, Brinch L et al (2000). A randomised study of allogeneic transplantation with stem cells from blood or bone marrow. Bone Marrow Transplant 25 : 1129 1136.
34. Hexner E (2006). The role of T cells in hematopoietic stem cell engraftment. Scientific World J 6 : 246 253.
35. Hirst LW, Jabs DA, Tutschka PJ, Green WR, Santos GW (1983). The eye in bone marrow transplantation. I. Clinical study. Arch Ophthalmol 101 : 580 584.
36. Holmberg L, Kikuchi K, Gooley TA et al (2006). Gastrointestinal graft-versus-host disease in recipients of autologous hematopoietic stem cells: incidence, risk factors, and outcome. Biol Blood Marrow Transplant 12 : 226 234.
37. Horwitz ME, Sullivan KM (2006). Chronic graft-versus-host disease. Blood Rev 20 : 15 27.
38. Huang XJ, Jiang Q, Chen H et al (2005). Low-dose methotrexate for the treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 36 : 343 348.
39. Imanguli MM, Pavletic SZ, Guadagnini JP, Brahim JS, Atkinson JC (2006). Chronic graft versus host disease of oral mucosa: review of available therapies. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 101 : 175 183.
40. Iyer RV, Hahn T, Roy HN et al (2005). Long-term use of oral beclomethasone dipropionate for the treatment of gastrointestinal graft-versus-host disease. Biol Blood Marrow Transplant 11 : 587 592.
41. Jabs DA, Wingard J, Green WR, Farmer ER, Vogelsang G, Saral R (1983). The eye in bone marrow transplantation. II. Histopathology. Arch Ophthalmol 101 : 585 590.
42. Jabs DA, Wingard J, Green WR, Farmer ER, Vogelsang G, Saral R (1989). The eye in bone marrow transplantation. III. Conjunctival graft-vs-host disease. Arch Ophthalmol 107 : 1343 1348.
43. Jack MK, Jack GM, Sale GM, Shulman HM, Sullivan KM (1983). Ocular manifestations of graft-v-host disease. Arch Ophthalmol 101 : 1080 1084.
44. Johnson DA, Jabs DA (1997). The ocular manifestations of graft-versus-host disease. Int Ophthalmol Clin 37 : 119 133.
45. Johnston LJ, Brown J, Shizuru JA et al (2005). Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 11 : 47 55.
46. Karwacka E, Oldakowska-Jedynak U, Brydak-Godowska J, Paczek L, Kecik D (2006). Pemphigoid-like ocular lesions in patients with graft-versus-host disease following allogeneic bone marrow transplantation. Transplant Proc 38 : 292 294.
47. Kawase E, Azuma N, Shioda Y, Kumagi M (2005). Infantile case of occlusive microvascular retinopathy after bone marrow transplantation. Jpn J Ophthalmol 49 : 318 320.
48. Kerty E, Vigander K, Flage T, Brinch L (1999). Ocular findings in allogeneic stem cell transplantation without total body irradiation. Ophthalmology 106 : 1334 1338.
49. Key T, Taylor CJ, Bradley JA, Taylor AL (2004). Recipients who receive a human leukocyte antigen-B compatible cadaveric liver allograft are at high risk of developing acute graft-versus-host disease. Transplantation 78 : 1809 1811.
50. Kim RY, Anderlini P, Naderi AA, Rivera P, Ahmadi MA, Esmaeli B (2002). Scleritis as the initial clinical manifestation of graft-versus-host disease after allogenic bone marrow transplantation. Am J Ophthalmol 133 : 843 845.
51. Kim H, Csaky KG, Gilger BC et al (2005). Preclinical evaluation of a novel episcleral cyclosporine implant for ocular graft-versus-host disease. Invest Ophthalmol Vis Sci 46 : 655 662.
52. Komanduri KV, Couriel D, Champlin RE et al (2006). Graft-versus-host disease after allogeneic stem cell transplantation: evolving concepts and novel therapies including photopheresis. Biol Blood Marrow Transplant 12 (1 Suppl 2 1 6.
53. Korbling M, Anderlini P (2001). Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter? Blood 98 : 2900 2908.
54. Krejci M, Doubek M, Buchler T, Brychtova Y, Vorlicek J, Mayer J (2005). Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease. Ann Hematol 84 : 681 685.
55. Krenger W, Rossi S, Piali L, Hollander GA (2000). Thymic atrophy in murine acute graft-versus-host disease is effected by impaired cell cycle progression of host pro-T and pre-T cells. Blood 96 : 347 354.
56. Lamey PJ, Lundy FT, Al-Hashimi I (2004). Sjogren's syndrome: a condition with features of chronic graft-versus-host disease: does duct cell adhesion or permeability play a role in pathogenesis? Med Hypotheses 62 : 825 829.
57. Lee SJ, Zahrieh D, Agura E et al (2004). Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood 104 : 1559 1564.
58. Leite SC, de Castro RS, Alves M et al (2006). Risk factors and characteristics of ocular complications, and efficacy of autologous serum tears after haematopoietic progenitor cell transplantation. Bone Marrow Transplant 38 : 223 227.
59. Lopez F, Parker P, Nadamanee A et al (2005). Efficacy of mycophenolate mofetil in the treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 11 : 307 313.
60. McDonald GB, Sullivan KM, Schuffler MD, Schulman HM, Thomas ED (1981). Esophageal abnormalities in chronic graft-versus-host disease in humans. Gastroenterology 80 (5 Pt 1 914 921.
61. Michallet M, Perrin MC, Belhabri A et al (1999). Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation. Bone Marrow Transplant 23 : 145 150.
62. Mohty M, Kuentz M, Michallet M et al (2002). Chronic graft-versus-host disease after allogeneic blood stem cell transplantation: long-term results of a randomized study. Blood 100 : 3128 3134.
63. Morris E, Thomson K, Craddock C et al (2004). Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood 104 : 3865 3871.
64. Murphy PT, Sivakumaran M, Fahy G, Hutchinson RM (1996). Successful use of topical retinoic acid in severe dry eye due to chronic graft-versus-host disease. Bone Marrow Transplant 18 : 641 642.
65. Nagler R, Barness-Hadar L, Lieba M, Nagler A (2006). Salivary antioxidant capacity in graft versus host disease. Cancer Invest 24 : 269 277.
66. Nakhleh RE, Miller W, Snover DC (1989). Significance of mucosal vs salivary gland changes in lip biopsies in the diagnosis of chronic graft-vs-host disease. Arch Pathol Lab Med 113 : 932 934.
67. Ogawa Y, Okamoto S, Kuwana M et al (2001). Successful treatment of dry eye in two patients with chronic graft-versus-host disease with systemic administration of FK506 and corticosteroids. Cornea 20 : 430 434.
68. Ogawa Y, Kuwana M, Yamazaki K et al (2003a). Periductal area as the primary site for T-cell activation in lacrimal gland chronic graft-versus-host disease. Invest Ophthalmol Vis Sci 44 : 1888 1896.
69. Ogawa Y, Okamoto S, Mori T et al (2003b). Autologous serum eye drops for the treatment of severe dry eye in patients with chronic graft-versus-host disease. Bone Marrow Transplant 31 : 579 583.
70. Ordemann R, Hutchinson R, Friedman J et al (2002). Enhanced allostimulatory activity of host antigen-presenting cells in old mice intensifies acute graft-versus-host disease. J Clin Invest 109 : 1249 1256.
71. Peris-Martinez C, Menezo JL, Diaz-Llopis M, Avino-Martinez JA, Navea-Tejerina A, Risueno-Reguillo P (2001). Multilayer amniotic membrane transplantation in severe ocular graft versus host disease. Eur J Ophthalmol 11 : 183 186.
72. Prentice HG, Blacklock HA, Janossy G et al (1984). Depletion of T lymphocytes in donor marrow prevents significant graft-versus-host disease in matched allogeneic leukaemic marrow transplant recipients. Lancet 1 : 472 476.
73. Remberger M, Kumlien G, Aschan J et al (2002). Risk factors for moderate-to-severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell tranplantation. Biol Blood Marrow Transplant 8 : 674 682.
74. Ringden O, Pihlstedt P, Markling L et al (1991). Prevention of graft-versus-host disease with T cell depletion or cyclosporin and methotrexate. A randomized trial in adult leukemic marrow recipients. Bone Marrow Transplant 7 : 221 226.
75. Ringden O, Remberger M, Ruutu T et al (1999). Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplantation Group. Blood 93 : 2196 2201.
76. Ringden O, Uzunel M, Rasmusson I et al (2006). Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 81 : 1390 1397.
77. Robinson MR, Lee SS, Rubin BI et al (2004). Topical corticosteroid therapy for cicatricial conjunctivitis associated with chronic graft-versus-host disease. Bone Marrow Transplant 33 : 1031 1035.
78. Rocha EM, Pelegrino FS, de Paiva CS, Vigorito CS, de Souza CA (2000). GVHD dry eyes treated with autologous serum tears. Bone Marrow Transplant 25 : 1101 1103.
79. Rodriguez V, Anderson PM, Trotz BA, Arndt CA, Allen JA, Khan SP (2005). Use of infliximab-daclizumab combination for the treatment of acute and chronic graft-versus-host disease of the liver and gut. Pediatr Blood Cancer 49 : 212 215.
80. Rzepecki P, Sarosiek T, Szczylik C et al (2006). Alemtuzumab, fludarabine and melphalan as a conditioning therapy in severe aplastic anemia and hypoplastic myelodysplastic syndrome - single center experience. Jpn J Clin Oncol 36 : 46 49.
81. Saito T, Shinagawa K, Takenaka K et al (2002). Ocular manifestation of acute graft-versus-host disease after allogeneic peripheral blood stem cell transplantation. Int J Hematol 75 : 332 334.
82. Sheidow TG, Sexton B, Hooper PL, Heathcote JG (2004). Vitritis as the primary manifestation of graft-versus-host disease: a case report with vitreous cytopathology. Can J Ophthalmol 39 : 667 671.
83. Socie G, Devergie A, Cosset JM et al (1990). Low-dose (one gray) total-lymphoid irradiation for extensive, drug-resistant chronic graft-versus-host disease. Transplantation 49 : 657 658.
84. Spinelli S, Chiodi S, Costantini S et al (2003). Female genital tract graft-versus-host disease following allogeneic bone marrow transplantation. Haematologica 88 : 1163 1168.
85. Spiryda LB, Laufer MR, Soiffer RJ, Antin JA (2003). Graft-versus-host disease of the vulva and/or vagina: diagnosis and treatment. Biol Blood Marrow Transplant 9 : 760 765.
86. Strouthidis NG, Francis PJ, Stanford MR, Graham EM, Holder GE, Bird AC (2003). Posterior segment complications of graft versus host disease after bone marrow transplantation. Br J Ophthalmol 87 : 1421 1423.
87. Sullivan KM, Witherspoon RP, Storb R et al (1988). Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood 72 : 546 554.
88. Sullivan KM, Agura E, Anasetti C et al (1991). Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 28 : 250 259.
89. Takami A, Mochizuki K, Okumura H et al (2006). Mycophenolate mofetil is effective and well tolerated in the treatment of refractory acute and chronic graft-versus-host disease. Int J Hematol 83 : 80 85.
90. Teachey DT, Bickert B, Bunin N (2006). Daclizumab for children with corticosteroid refractory graft-versus-host disease. Bone Marrow Transplant 37 : 95 99.
91. Thomas ED, Lochte HL Jr., Lu WC, Ferrebee JW (1957). Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. New Engl J Med 257 : 491 496.
92. Tutschka P, T R, Beschorner WE, Santos GW (1982). Chronic graft-versus-host disease in the rat radiation chimera, I: clinical features, hematology, histology and immunopathology in long-term chimeras. Transplantation 34 : 289 294.
93. Van Lint MT, Uderzo C, Locasciulli A et al (1998). Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation. Blood 92 : 2288 2293.
94. Vigorito AC, Azevedo WM, Marques JF (1998). A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies. Bone Marrow Transplant 22 : 1145 1151.
95. Vogelsang GB, Farmer ER, Hess AD et al (1992). Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med 326 : 1055 1058.
96. Wagner JL, Seidel K, Boeckh M, Storb R (2000). De novo chronic graft-versus-host disease in marrow graft recipients given methotrexate and cyclosporine: risk factors and survival. Biol Bone Marrow Transpl 6 : 633 639.
97. Wolff D, Roessler V, Steiner B et al (2005). Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept. Bone Marrow Transplant 35 : 1003 1010.
98. Yeh PT, Hou YC, Lin WC, Wang IJ, Hu FR (2006). Recurrent corneal perforation and acute calcareous corneal degeneration in chronic graft-versus-host disease. J Formos Med Assoc 105 : 334 339.
99. Yoshida A, Kawano Y, Kato K et al (2006). Apoptosis in perforated cornea of a patient with graft-versus-host disease. Can J Ophthalmol 41 : 472 475.
100. Zeng D, Lewis D, Dejbackhsh-Jones S (1999). Bone marrow NK1.1(-) and NK1.1(+) T cells reciprocally regulate acute graft versus host disease. J Exp Med 189 : 1073 1081.
101. Zorn E (2006). CD4+CD25+ regulatory T cells in human hematopoietic cell transplantation. Semin Cancer Biol 16 : 150 159.